Ashkon Software



BIB - ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology logo BIB (ProShares Ultra Nasdaq Biotechnology) is an exchange-traded fund (ETF) managed by ProShares Advisors LLC. The ETF seeks to provide investors with twice (2x) the daily return of the Nasdaq Biotechnology Index, which is a benchmark that tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market.

As a leveraged ETF, BIB uses financial derivatives and other investment strategies to amplify the daily returns of the underlying index. This means that if the Nasdaq Biotechnology Index rises by 1% on a given day, BIB should deliver a return of 2% (before fees and expenses). However, if the index falls by 1%, BIB would be expected to deliver a loss of 2%.

As of September 2021, the BIB ETF had total net assets of around $2.5 billion and was invested in a diversified portfolio of biotechnology and pharmaceutical companies. The fund's top holdings included companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.

In terms of performance, BIB has delivered strong returns over the long term, with an annualized return of around 22% since its inception in April 2007 (as of September 2021). However, investors should keep in mind that leveraged ETFs like BIB can be highly volatile and carry significant risks. Additionally, the ETF charges a relatively high expense ratio of 0.95%, which is higher than the average expense ratio for ETFs in the biotechnol




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer